50 billion!

Medical Network News on September 3rd, the interim performance report of listed companies has been disclosed.
According to incomplete statistics, 319 A-share and Hong Kong-listed pharmaceutical companies announced H1 R&D investment in 2021 (see the end of the article for details), with a total amount of nearly 50 billion yuan , Hengrui, Fosun, CSPC, Cinda and other blockbuster Class 1 new drugs are submitted for production
.
98 pharmaceutical companies have invested more than 100 million yuan in R&D, and 9 companies have invested more than 1 billion yuan (5 in the same period last year); nearly 80% of pharmaceutical companies have shown positive growth in R&D investment, and 27 have soared over 100%; innovative companies dominated, and 9 pharmaceutical companies accounted for R&D investment The proportion of revenue exceeds 100%
.

Hengrui, Fosun,
CSPC .
.
.
9 pharmaceutical companies invested more than 1 billion in R&D in 2021 H1,160 pharmaceutical companies invested more than 50 million in R&D in 2021 (120 companies in the same period last year), of which 98 were in R&D More than 100 million yuan was invested (68 companies in the same period last year)
.
9 companies including BeiGene, Hengrui, Zai Lab, Fosun, China Biopharmaceuticals, CSPC, Shanghai Pharmaceuticals, GenScript, and Cinda exceeded RMB 1 billion
.
Companies that have invested more than 1 billion yuan in R&D Note: The exchange rate is calculated on September 1, and BeiGene has always been willing to “smash” heavily in R&D, and it has put pressure on many listed pharmaceutical companies in R&D investment
.
In 2021, H1 R&D expenditure was US$677 million (approximately 4.
38 billion yuan), an increase of 14.
7% over the same period last year, accounting for 89.
5% of revenue
.
As of the end of the reporting period, the global clinical development team has more than 1,700 people, with about 50 drugs or drug candidates in the commercialization or clinical development stage, and more than 95 clinical trials are ongoing or planned
.
At present, BeiGene has three self-developed Class 1 new drugs approved for marketing, namely Tilelizumab (PD-1), Zebutinib (BTK inhibitor) and Pamipali (PARP inhibitor) ; The imported daltuximab β (GD2 monoclonal antibody), desulumab (IgG2 monoclonal antibody), etc.
were approved for import
.
Among the new drugs being researched, the first-class new drugs Ociperlimab (TIGIT antibody) and Sitravatinib (selective kinase inhibitor) have been in phase III clinical trials in China, and both are used to treat metastatic non-small cell lung cancer
.
Although Hengrui Medicine's R&D investment is not the most, but the number of new drugs in the clinical application and above stage is ahead of other domestic companies, and it is known as "the first brother of innovative drugs"
.
In 2021, H1's R&D investment was 2.
581 billion yuan, an increase of 38.
5% over the same period last year, accounting for 19.
4% of revenue
.
As of the end of the reporting period, more than 240 clinical projects were carried out at home and abroad, of which 23 were international multi-center clinical projects
.
At present, Hengrui Pharmaceuticals has 8 innovative drugs approved for marketing.
Except for Thiopefilgrastim, the remaining 7 are all Class 1 new drugs
.
Among the first class of new drugs, the independently developed Hengligliflozin (SGLT-2 inhibitor), Repagliptin (DPP4 inhibitor), SHR6390 (CDK4/6 selective inhibitor), and the imported Pranabrin ( GEF-H1 activator) has been reported for production
.
Fosun Pharma's H1 R&D investment in 2021 was 1.
954 billion yuan, an increase of 15.
69% over the same period last year, accounting for 11.
53% of revenue
.
As of the end of the reporting period, the company had nearly 2,600 R&D personnel and 240 projects under development, including 30 small molecule innovative drugs, 29 bio-innovative drugs, 13 licensed introductions of innovative drugs, 18 biosimilar drugs, and 103 generic drugs.
consistency evaluation items 38 and so on
.
At present, Fosun Pharma has approved 2 innovative drugs (CAR-T product Akirensai and imported Class 5.
1 new drug Avatropol) and 3 biosimilar drugs
.
Among the new drugs being researched, the new class 1 drug slulimumab (PD-1 monoclonal antibody), the imported class 5.
1 new drug opicapone (COMT inhibitor), bevacizumab biosimilar drugs, etc.
have been reported for production; import 1 The new class of drug Tenapanor (NHE3 inhibitor) is undergoing phase III clinical trials for end-stage renal disease-hemodialysis
.
CSPC's H1 research and development expenses in 2021 reached 1.
613 billion yuan, an increase of 11.
0% over the same period last year, accounting for 11.
54% of revenue
.
As of the end of the reporting period, the company has about 300 research projects, including more than 40 small-molecule innovative drugs, more than 40 large-molecule innovative drugs, and more than 30 new preparations
.
At present, CSPC's innovative drugs are mainly butylphthalide series products
.
Among the new drugs being developed, the first class new drug Rezetinib (third-generation EGFR inhibitor) and the imported 5.
1 class new drug duensibu (PI3K-δ/PI3K-γ dual inhibitor) have been reported for production; 40 products are undergoing clinical trials , Class 1 new drugs such as DBPR108 (DPP-4 inhibitor) and SKLB1028 (multi-target protease inhibitor) have entered phase III clinical trials
.
Shanghai Pharmaceuticals, a leading pharmaceutical distribution company, is not inferior to the pharmaceutical industry.
According to the established innovation and transformation strategy, the company has more than tripled its R&D investment in the past five years
.
In 2021, H1 R&D investment is 1.
139 billion yuan, an increase of 51.
90% over the same period last year, accounting for 9.
04% of the pharmaceutical industry's revenue
.
As of the end of the reporting period, the company entered the pre-clinical and follow-up research phases of the innovative drug pipeline with 35 projects, of which 24 projects have entered clinical trials or have been on the market
.
From the perspective of research and development progress, the first class of new drug SPH3127 (a new oral renin inhibitor) is undergoing phase III clinical trials in China for the treatment of primary mild to moderate hypertension ; the introduced new drug Prolgolimab injection (PD-1 monoclonal antibody) ) Is undergoing phase III clinical trials for the treatment of progressive, recurrent or metastatic cervical cancer
.
Biopharmaceutical innovation company Cinda Biotech invested 1.
042 billion yuan in H1 R&D in 2021, an increase of 29.
00% over the same period last year, accounting for 53.
70% of revenue
.
As of the end of the reporting period, the company has 25 products under development, of which 5 have been approved for listing, 1 has been submitted for NDA, 5 are at a critical stage, and 14 are at other clinical stages
.
Since its establishment, Cinda Biosciences has achieved commercialization of 5 new drugs (3 biosimilar drugs) in 10 years
.
Among the new drugs being researched, the imported 5.
1 class new drug Pemigatinib tablets (FGFR tyrosine kinase inhibitor) have been reported for production, IBI-310 (CTLA-4 antibody), IBI-306 (PCSK9 antibody), IBI-376 (PI3Kδ inhibitor) , IBI-326 (BCAR CAR-T), etc.
are in the critical phase II/III clinical stage
.

Zai Lab, Zhifei, Maibo.
.
.
27 pharmaceutical companies' R&D investment has soared by more than 100%
.
Among the 319 pharmaceutical companies that have disclosed their R&D investment, 254 pharmaceutical companies have shown a positive increase in R&D investment compared with the same period last year, accounting for Nearly 80%; 27 pharmaceutical companies' R&D investment has increased by 100% or more year-on-year, of which 14 have invested more than 100 million yuan in R&D
.

　　Companies with R&D investment exceeding 100 million and a growth rate of over 100% Zai Lab has enriched its product pipeline by means of “self-research + introduction”, and its R&D investment is not inferior to innovative pharmaceutical companies that focus on self-research
.
In 2021, H1 R&D investment was 346 million U.
S.
dollars (approximately 2.
24 billion yuan), which has exceeded the investment for the whole year of last year, a year-on-year increase of 239.
1%, accounting for 606.
7% of revenue
.
As of August 9, the company has 12 products in the late stage of development
.
Currently tripod and then medicine at home there are 3 new drugs commercialized, including a class of drugs nila Palley (PARP inhibitors), imported 5.
1 class of drugs such as imatinib Swiss school
.
Among the new drugs being researched, the imported class 1 new drugs Efgartigimod (FcRn antibody) and Margetuximab (Fc monoclonal antibody targeting HER2) are undergoing phase III and phase II/III clinical trials
.
Zhifei Biology and Cansino are both vaccine research and development and production companies, And the growth rate of H1 R&D investment in 2021 will exceed 400%, of which Zhifei Biological R&D investment is 790 million yuan, accounting for 6.
00% of revenue; Cansino R&D investment is 567 million yuan, accounting for 27.
50% of revenue
.
As of the end of the reporting period, Zhifei has 26 projects in clinical trials and preclinical research phases, covering human vaccines and biological products for infectious diseases such as tuberculosis, pneumonia, meningitis, influenza, rabies, etc.
, including ZF2001, 15-valent pneumococcal combination Vaccines, freeze-dried human rabies vaccine (MRC-5 cells), tetravalent influenza virus split vaccine, etc.
are in phase III clinical trials
.
CanSino has 16 innovative vaccine products under development, covering 13 indications such as Ebola virus disease, meningitis, new coronary pneumonia, DPT, pneumonia, tuberculosis, and herpes zoster, MCV4 (quadrate meningococcal conjugate vaccine ) NDA has been submitted, and PCV13i (13-valent pneumonia conjugate vaccine) is undergoing phase III clinical trials
.

　　Rongchang, Keystone, Zejing.
.
.
9 pharmaceutical companies have over 100%
R&D intensity.
From the perspective of R&D intensity (R&D investment accounts for the proportion of revenue), 84 pharmaceutical companies have R&D intensity of 10% or more.
Zejing.
.
.
9 pharmaceutical companies more than 100%; 18 pharmaceutical companies are temporarily unprofitable (no products are approved for commercial sales or no product sales generate revenue), including Kangfang Bio, Shenzhou Cell, and Yasheng Pharmaceutical The R&D investment of more than 300 million yuan
.
Companies with a R&D intensity of 100% and above As the leading domestic ADC track company, Rongchang Bio will invest 327 million yuan in H1 R&D in 2021, an increase of 73.
50% over the same period last year, accounting for 1118.
50% of revenue
.
As of the end of the reporting period, the company has a product line of more than 10 drug candidates, including 4 ADC drugs, 1 PD-L1 monoclonal antibody, 3 double antibodies, and 2 fusion proteins
.
At present, Rongchang Biologics has approved two Class 1 new drugs for the market.
Taltazep is a TACI-Fc fusion protein, and vedixituzumab is the first ADC drug in China.

.
Seven class 1 new drugs are in clinical development, RC28 (VEGF/FGF fusion protein) has entered phase II clinical trials, and two ADC drugs RC88, RC108 and PD-1 monoclonal antibody RC98 are in phase I clinical trials
.
Ou Kang Weishi, which is ahead of the gold track in ophthalmology, invested 245 million yuan in H1 R&D in 2021, an increase of 186.
80% over the same period last year, accounting for 1175.
50% of revenue
.
As of the end of the reporting period, the company's product portfolio has expanded to 18 drugs, covering anterior and posterior eye diseases
.
Among the new drugs being researched, the imported class 5.
1 new drug fluocinolone intravitreal implant (OT-401) has been reported for production; 5 main candidate drugs are in phase III clinical trials in China, including the imported class 5.
1 new drug cetirizine hydrochloride eye drops dexamethasone implant agent imports a class of drugs NCX470 eye drops and the like
.
Cornerstone Pharmaceuticals, which focuses on tumor immunotherapy combination therapy, will spend 513 million yuan in H1 R&D in 2021, a slight decline from the same period last year, accounting for 645.
80% of revenue
.
At present, the company has established a product pipeline consisting of 15 tumor drug candidates, and will focus on ADC drugs and multispecific antibodies in the future
.
CStone Pharmaceuticals currently has two new drugs approved for marketing, including the imported Class 5.
1 new drug Avatinib (KIT/PDGFRA inhibitor) and the imported Class 1 new drug Pratinib (RET inhibitor)
.
Among the new drugs being researched, the class 1 new drug sugarizumab (PD-L1 monoclonal antibody) and the imported class 5.
1 new drug Afnib (IDH1 inhibitor) have been reported for production, and the company expects to submit more than five NDA applications in 2022
.

　　Sources of companies that have invested more than 10 million yuan in R&D: Minet database, public company announcements, etc.
Note: The data statistics are as of September 1 and are purely compiled by hand.
If there are any omissions, please correct me!